Janice Siciliano
Internal Medicine · Sea Girt, NJNPI 1689612129
Payments from drug & device makers
Across 410 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$892
- Boehringer Ingelheim$701
- Lilly USA, LLC$492
- Abbott$401
- AbbVie$343
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,78499%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $1,206 |
| Novo Nordisk | 70 | $892 |
| Boehringer Ingelheim | 56 | $701 |
| Lilly USA, LLC | 34 | $492 |
| Abbott | 26 | $401 |
| AbbVie(2 entities) | 24 | $343 |
| Exact Sciences | 14 | $320 |
| Merck | 17 | $250 |
| GSK | 16 | $238 |
| Pfizer | 10 | $147 |
| Sanofi-aventis U.S. LLC | 10 | $140 |
| Kowa Pharmaceuticals America, Inc. | 10 | $137 |
| Johnson & Johnson | 7 | $101 |
| Amarin Pharma, Inc. | 7 | $99 |
| Biohaven Pharmaceuticals, Inc. | 5 | $70 |
| Bayer | 4 | $57 |
| Lundbeck LLC | 3 | $53 |
| Genentech USA, Inc. | 3 | $42 |
| Dexcom, Inc. | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Eisai Inc. | 2 | $26 |
| Astellas Pharma US Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
How this compares
$5,864 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $118,470 |
| MounjaroTirzepatide | 83 | $89,070 |
| FarxigaDapagliflozin Propanediol | 65 | $80,984 |
| JardianceEmpagliflozin | 48 | $62,283 |
| TrulicityDulaglutide | 32 | $46,481 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $32,958 |
| JanuviaSitagliptin Phosphate | 21 | $26,622 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $25,904 |
| ProliaDenosumab | 11 | $19,049 |
| EliquisApixaban | 22 | $17,384 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $17,142 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $13,818 |
| ConcertaMethylphenidate Hcl | 22 | $13,603 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $12,901 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $492 | $135,552115 claims |
| Novo NordiskOzempic | $892 | $118,470112 claims |
| AstraZenecaFarxiga | $1,206 | $80,98465 claims |
| Boehringer IngelheimJardiance, Synjardy | $701 | $75,18466 claims |
| MerckJanuvia, Janumet | $250 | $52,52645 claims |
| GSKBreo Ellipta, Anoro Ellipta | $238 | $30,95944 claims |
| PfizerEliquis | $147 | $17,38422 claims |
| Johnson & JohnsonConcerta | $101 | $13,60322 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $140 | $9,17111 claims |
| AbbVieSynthroid | $343 | $7,13878 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Sea Girt
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.